Feb. 01, 2016News & Opinions
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to UK-Swedish drug maker AstraZeneca for its oral poly ADP-ribose polymerase (PARP) inhibitor Lynparza (olaparib) for treating a certain type of ...
Jan. 29, 2016News & Opinions
The US Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) submitted by UK-Swedish drugmaker AstraZeneca in partnership with Canadian drugs firm Valeant Pharmaceuticals for the psoriasis ...
Jan. 28, 2016News & Opinions
Three major drugs companies have joined forces with three leading UK universities to translate ground-breaking academic science into new medicines for a broad range of diseases.
Jan. 26, 2016News & Opinions
More than 80 international drug and biotechnology companies have urged governments to work with them to combat the emergence of drug-resistant superbugs, according to a report by news agency Reuters.
Jan. 13, 2016News & Opinions
Five major internationally active drugmakers, including American biotech firms Amgen and Celgene, along with pharmaceutical giant Pfizer and non-US players such as Glaxo SmithKline of the UK and Merck
Jan. 05, 2016News & Opinions
Swedish drugmaker AstraZeneca has gained approval from the US Food and Drug Administration (FDA) to market Zurampic, a treatment for gout, the debilitating form of inflammatory arthritis caused by raised levels of uric acid, or ...
Dec. 18, 2015News & Opinions
The third week of December was a busy one for AstraZeneca.
Dec. 15, 2015News & Opinions
AstraZeneca has confirmed speculation that it is “exploring potential strategic options” with Acerta Pharma, a privately owned biotech firm with operations in the Netherlands and California.
Dec. 11, 2015News & Opinions
Catalent Pharma Solutions has signed an exclusive long term supply agreement with Pfizer to produce over-the-counter heartburn treatment, Nexium 24HR (esomeprazole), branded as Nexium Control outside the US, for which the US drugmaker in ...
Nov. 30, 2015News & Opinions
Drugs firms AstraZeneca and Sanofi are to exchange 210,000 compounds from their libraries to help boost their search for new small-molecule medicines.
The latest information directly via newsletter.